• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Wall Street Beat

Ahead of G7 launch, Dexcom CEO plans for ‘more activity than we’ve ever seen’ in 2022

January 14, 2022 By Sean Whooley

Dexcom G7 Wearable Top (1)

With a major product approval and launch in its sights, Dexcom prepares for a big year in 2022. Across 2021, Dexcom (NSDQ:DXCM) took several steps forward. The company touted its next-generation G7 continuous glucose monitor (CGM) and announced a significant regulatory nod and partnership for real-time application programming interfaces (APIs), to list a couple. As […]

Filed Under: Auto-injectors, Big Data, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Regulatory/Compliance, Wall Street Beat Tagged With: Dexcom, Garmin, Insulet, Medtronic

Novo Nordisk completes acquisition of Dicerna Pharmaceuticals

December 28, 2021 By Sean Whooley

Novo Nordisk Dicerna Pharmaceuticals

Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed. Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna at 11:59 p.m. […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: Dicerna Pharmaceuticals, Novo Nordisk

Waiting period for Novo Nordisk’s proposed acquisition of Dicerna expires

December 27, 2021 By Sean Whooley

Novo Nordisk Dicerna Pharmaceuticals

Dicerna Pharmaceuticals (NSDQ:DRNA) announced that a waiting period for a proposed acquisition by Novo Nordisk (NYSE:NVO) has expired. The announcement, made on Dec. 25, confirmed that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m. ET on […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Dicerna Pharmaceuticals, Novo Nordisk

Zacks says Medtronic will gain from expanded CMS coverage for CGMs

December 23, 2021 By Sean Whooley

Medtronic logo updated

Zacks Equity Research today reported that Medtronic (NYSE:MDT) stands to gain from yesterday’s CMS coverage expansion for diabetes technology. CMS’s expanded coverage, confirmed by Medtronic yesterday, covers all types of CGMs (continuous glucose monitors), including adjunctive and non-adjunctive CGMs. The coverage includes CGMs that integrate with Medtronic insulin pumps. Zacks said the new rule will likely […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Wall Street Beat Tagged With: Medtronic

Report: Insulet expects delays in FDA review for Omnipod 5 with launch pushed back

December 6, 2021 By Sean Whooley

Insulet OmniPod 5

The highly anticipated launch of the Insulet (NSDQ:PODD) Omnipod 5 may not come as soon as thought as an FDA review drags on. SeekingAlpha reported that Insulet CEO Shacey Petrovic, speaking at the Nasdaq Investor Conference, said the regulatory agency will likely not complete its review of the next-generation Omnipod 5 before the end of […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Wall Street Beat Tagged With: FDA, Insulet, Tandem Diabetes Care

Senseonics posts Q3 earnings beat, hopes for new FDA approval soon

November 9, 2021 By Sean Whooley

Eversense CGM Senseonics

Senseonics (NYSE:SENS) shares ticked up slightly on third-quarter results that beat the consensus earnings forecast. The Germantown, Maryland-based company posted profits of $42.9 million, or 8¢ per share, on sales of $3.5 million for the three months ended Sept. 30, 2021, for a massive bottom-line swing out of the red on sales growth of nearly […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), MassDevice Earnings Roundup, Patient Monitoring, Wall Street Beat Tagged With: Senseonics

Stevanato Group beats The Street in Q3, raises guidance

November 9, 2021 By Sean Whooley

Stevanato Group

Stevanato Group (NYSE:STVN) shares hit a snag today despite third-quarter results that beat the consensus forecast. The Piombino Dese, Italy-based drug delivery technology developer posted profits of $21.6 million, or 8¢ per share, on sales of $248.6 million for the three months ended Sept. 30, 2021, for a 12.5% bottom-line gain on sales growth of […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Stevanato Group

Insulet posts Q3 sales beat, remains on track for Omnipod 5 clearance

November 5, 2021 By Sean Whooley

Insulet OmniPod 5

Insulet (NSDQ:PODD) shares ticked up today on third-quarter results that were mixed compared to the consensus forecast. The Acton, Massachusetts-based tubeless insulin pump technology developer posted profits of $12.6 million, or 18¢ per share, on sales of $275.6 million for the three months ended Sept. 30, 2021, for an 8.6% bottom-line gain on sales growth […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Insulet

BD ticks up on Street-beating Q4, sets 2022 guidance range

November 4, 2021 By Sean Whooley

This is the logo of BD.

BD (NYSE:BDX) shares rose today on fourth-quarter results that came in ahead of the consensus forecast. The Franklin Lakes, New Jersey-based medtech posted profits of $242 million, or 84¢ per share, on sales of $5.1 billion for the three months ended Sept. 30, 2021, more than doubling its bottom line on sales growth of 7.3%. Get […]

Filed Under: Business/Financial News, Diagnostics, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: BD, coronavirus, COVID-19

Tandem nosedives after hours despite strong Q3, raised guidance

November 3, 2021 By Sean Whooley

Tandem Diabetes Care tslim_X2_Insulin_Pump_Front_View_Control-IQ_RGB

Tandem Diabetes Care (NSDQ:TNDM) shares took a massive hit after hours today on third-quarter results that beat the consensus forecast. TNDM shares were down 12.3% at $124.01 per share after the markets closed. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day down 0.1%. The […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Tandem Diabetes Care

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Interim pages omitted …
  • Page 193
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS